Bio-Techne Corporation

NasdaqGS:TECH Stok Raporu

Piyasa değeri: US$8.1b

Bio-Techne Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Bio-Techne kazanç ve gelirin sırasıyla yıllık 23.5% ve 6.7% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 24.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 15.4% olacağı tahmin edilmektedir.

Anahtar bilgiler

23.5%

Kazanç büyüme oranı

24.05%

EPS büyüme oranı

Life Sciences kazanç büyümesi16.0%
Gelir büyüme oranı6.7%
Gelecekteki özkaynak getirisi15.42%
Analist kapsamı

Good

Son güncelleme22 Apr 2026

Gelecekteki son büyüme güncellemeleri

Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Nov 08
Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Recent updates

TECH: Spatial And Clinical Platforms Will Support Balanced Future Earnings Potential

Analysts have reset their price targets on Bio-Techne to $56.78 from $65.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Rolled out a new brand architecture that organizes offerings into three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics.

TECH: Clinical And Spatial Biology Platforms Will Support Higher Future Earnings Multiple

Analysts have trimmed their price target on Bio-Techne to about $65, with updated assumptions reflecting slightly adjusted discount rates, revenue growth expectations, profit margins, and a modest shift in projected future P/E levels. What's in the News Expanded COMET spatial biology portfolio with new SPYRE Focus Panels and SPYRE Amplification Kits, plus updated HORIZON Image Analysis Software to support more flexible and sensitive tissue analysis workflows (Key Developments).

TECH: Clinical Platform Adoption Will Support Higher Future Earnings Multiple

Analysts have lifted their price target on Bio-Techne to $65.41, citing updated assumptions that reflect slightly higher projected revenue growth, a modestly stronger profit margin, and a small adjustment to the discount rate and future P/E expectations. What's in the News Ella benchtop immunoassay platform receives CE-IVD marking and becomes available for clinical use in the European Union, supporting in-house test development, clinical trials, and translational activities on a validated platform (Key Developments).

TECH: Multiomic Platform Expansion Will Support Higher Future Earnings Multiple

Analysts have raised their price target for Bio-Techne to $65.41 from $61.03, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple. What's in the News The Ella benchtop immunoassay platform received CE-IVD marking, making it available for clinical use in the European Union and positioning it as an option for in-house test development, clinical trials, and other translational activities (Key Developments).

TECH: Multiomic Platforms And 3D Workflows Will Support A Steady Forward Outlook

Narrative Update on Bio-Techne Analysts have adjusted their price target on Bio-Techne from $70.00 to $75.25, citing updated assumptions for revenue growth, profit margin, discount rate and future P/E that collectively support a higher assessed fair value. What’s in the News Ella benchtop immunoassay platform received CE-IVD marking and is now available for clinical use in the European Union.

There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings

Feb 12
There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings

TECH: Multiomic Platform Progress Will Contrast With Excessive Long Term Earnings Multiple

Analysts have lifted their fair value estimate for Bio-Techne by roughly $0.72 to reflect slightly stronger assumptions on revenue growth, profit margins, and the discount rate, along with a modestly lower future P/E. What's in the News Bio-Techne launched Cultrex Synthetic Hydrogel, a fully defined synthetic extracellular matrix aimed at more reproducible and scalable 3D stem cell and organoid research, reducing reliance on animal component derived matrices and supporting new approach methodologies in drug screening, toxicology, and personalized medicine (Key Developments).

TECH: Multiomic Automation And Buybacks Will Support A Steady Forward Outlook

Narrative Update on Bio-Techne Analysts have nudged their fair value estimate for Bio-Techne to US$70.00 per share from about US$69.17, citing updated assumptions around discount rates, long term revenue growth, profit margins and future P/E expectations. What's in the News Spatial biology brand Lunaphore is partnering with the Wyss Center for Bio and Neuroengineering in Geneva to build an automated workflow for simultaneous RNA and protein detection in 3D specimens.

Bio-Techne: Recovery Likely Coming, But Is There Enough Re-Rating Potential?

Jan 08

TECH: Multiomic Partnerships And Automation Will Support A Steady Forward Outlook

Analysts have kept their fair value estimate for Bio-Techne steady at about US$69.17, with small tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions driving a refined but directionally unchanged price target view. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, targeting higher resolution multiomic analysis in intact samples and broader use of spatial biology tools in research and diagnostics (Key Developments).

TECH: Multiomic Expansion And Margin Improvement Will Support Balanced Future Outlook

Analysts have raised their price target on Bio-Techne from approximately 53 dollars to about 60 dollars, citing expectations for modestly faster revenue growth, improving profit margins, and a higher justified future price to earnings multiple. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, aiming to extend multiomic spatial biology from 2D into 3D and reduce reliance on animal models (Key Developments).

TECH: Share Buyback Completion And New Partnerships Will Maintain Steady Outlook

Analysts have maintained Bio-Techne's price target at $69.17, citing minor adjustments to discount rate and forward P/E assumptions. Overall sentiment and company outlook remain steady.

TECH: Share Buyback Momentum Will Drive Stronger Performance Ahead

Narrative Update on Bio-Techne Analysts have increased their price target for Bio-Techne from $67.83 to $69.17, citing improved revenue growth and higher projected profit margins as key drivers behind the upward adjustment. What's in the News Bio-Techne successfully repurchased 500,000 shares between July and September 2025, completing a $124.06 million buyback under its May 2025 program (Buyback Tranche Update).

Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Nov 08
Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts Think

TECH: Product Advances And Index Changes Will Influence Future Demand For Precision Tools

Analysts have nudged their price target for Bio-Techne higher, raising it by $0.75 to $67.83. They cite modest improvements in profitability expectations and a slightly increased fair value assessment.

Chronic Disease Trends And Precision Medicine Will Shape Demand

Narrative Update on Bio-Techne Analysts have raised their price target for Bio-Techne from $66.23 to $67.08. This change reflects modest improvements in profit margin expectations, even though revenue growth forecasts have been slightly reduced.

Chronic Disease Trends And Precision Medicine Will Shape Demand

Bio-Techne's consensus price target saw only a minimal increase to $65.31, as both future P/E and revenue growth forecasts remained largely unchanged. What's in the News Bio-Techne formed a strategic partnership to distribute Spear Bio's ultrasensitive immunoassays, enabling detection of low-abundance biomarkers in neurology, initially focusing on translational research in Alzheimer's disease.

Investors Still Waiting For A Pull Back In Bio-Techne Corporation (NASDAQ:TECH)

Jul 28
Investors Still Waiting For A Pull Back In Bio-Techne Corporation (NASDAQ:TECH)

What Does Bio-Techne Corporation's (NASDAQ:TECH) Share Price Indicate?

May 29
What Does Bio-Techne Corporation's (NASDAQ:TECH) Share Price Indicate?

Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain

Feb 27
User avatar

Innovations In Molecular Diagnostics And Decisive Focus On Growth Verticals Promise Revenue Surge Amid Challenges

Bio-Techne's investment in advanced diagnostics and specialized instruments like Leo suggests strong potential for revenue growth from increased sales and market adoption.

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:TECH - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
6/30/20281,426266N/AN/A5
6/30/20271,30022839346311
6/30/20261,22519626126912
12/31/20251,21681223249N/A
9/30/20251,21778224251N/A
6/30/20251,22073257288N/A
3/31/20251,209132221265N/A
12/31/20241,196158254305N/A
9/30/20241,172151245303N/A
6/30/20241,159168236299N/A
3/31/20241,154203251307N/A
12/31/20231,145224225276N/A
9/30/20231,144247215258N/A
6/30/20231,137285216254N/A
3/31/20231,124271233274N/A
12/31/20221,120262252296N/A
9/30/20221,118292285333N/A
6/30/20221,106272280325N/A
3/31/20221,076225302345N/A
12/31/20211,030210308346N/A
9/30/2021985177295335N/A
6/30/2021931140308352N/A
3/31/2021848184225275N/A
12/31/2020799175201250N/A
9/30/2020760248179231N/A
6/30/2020739229153205N/A
3/31/2020755187170216N/A
12/31/2019745195165207N/A
9/30/201973493N/A183N/A
6/30/201971496N/A182N/A
3/31/2019703121N/A191N/A
12/31/201868296N/A173N/A
9/30/2018661128N/A165N/A
6/30/2018643126N/A170N/A
3/31/2018619112N/A156N/A
12/31/2017599114N/A160N/A
9/30/201757773N/A162N/A
6/30/201756376N/A144N/A
3/31/201754174N/A129N/A
12/31/201652882N/A141N/A
9/30/2016517101N/A138N/A
6/30/2016499104N/A144N/A
3/31/2016482105N/A145N/A
12/31/201546599N/A138N/A
9/30/2015456107N/A135N/A
6/30/2015452108N/A139N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: TECH 'nin tahmini kazanç büyümesi (yıllık 23.5% ) tasarruf oranının ( 3.4% ) üzerindedir.

Kazançlar ve Piyasa: TECH şirketinin kazançlarının (yıllık 23.5% ) US pazarından (yıllık 15.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: TECH şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: TECH şirketinin gelirinin (yıllık 6.7% ) US pazarından (yıllık 11% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: TECH şirketinin gelirinin (yıllık 6.7% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: TECH 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 15.4 %).

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/04/30 14:32
Gün Sonu Hisse Fiyatı2026/04/30 00:00
Kazançlar2025/12/31
Yıllık Kazançlar2025/06/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Bio-Techne Corporation 25 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
David ToungArgus Research Company
Catherine Ramsey SchulteBaird
Robert WassermanBenchmark Company